Navigation Links
Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
Date:7/20/2009

London, July 20 /PRNewswire/ -- There has been a recent upsurge in Merger & Acquisition (M&A) activities in the pharmaceutical and biotechnology space. While the economic downturn and related credit crunch has had an impact, this alone cannot account for the recent M&A mania, which has including four mega M&As in the first half of 2009.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"The real intention behind these mergers remains a question, as past mergers have not yielded substantial value addition in terms of R&D productivity," says Frost & Sullivan Senior Research Analyst Ranjith Gopinathan.

To look at these Mergers & Acquisitions in the Pharmaceutical and Biotechnology industry, the Healthcare Group at Frost & Sullivan will be hosting a complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2 p.m. BST/ 1 p.m. GMT.

Highlights of this briefing will include an analysis of the factors contributing to the increasing consolidation in the market, the impact of the economic downturn, as well as funding sources for biotech companies. The briefing will also look at key restraints for M&A activities in the pharma-biotech industry and provide a future M&A outlook. The discussion will benefit venture capitalists, investment banks, pharma and biotech companies as well as academic institutions.

"The global downturn's detrimental impact on funding availability coupled with an average 30 per cent decline in the value of biotech firms, means that outright acquisitions rather than complex licensing deals are an attractive proposition," concludes Gopinathan.

To participate in this briefing, please email Patrick Cairns at

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
2. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
5. Simcere Pharmaceutical Group Notice of Annual General Meeting
6. Amylin Pharmaceuticals to Webcast Second Quarter Results
7. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
8. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
9. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... (Nasdaq: ARNA ) today announced it will report ... closes on Monday, May 11, 2009. That same afternoon, Jack ... Hoffman, Arena,s Vice President, Finance and Chief Financial Officer, will ... p.m. Pacific Time) to discuss the financial results for the ...
... On Thursday, May 7, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC) management team will host a conference call to discuss the Company,s ... Conference Call Numbers, ... 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time, ...
... Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or ... three-month period ended March 31, 2009. , "The first ... very positive results in several of our combination REOLYSIN(R) ... of Oncolytics. "We continue to report clinical benefit in ...
Cached Biology Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 3Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 3Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 4Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 5Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 6Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 7Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 8
(Date:4/22/2014)... Biotechnology scientists must be aware of the broad ... guidelines, according to a new paper from Rice University,s ... current issue of the journal Regenerative Medicine , ... Supreme Court ruling in the case Association for Molecular ... are unpatentable. The court case and rulings garnered discussion ...
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and ... this week report that they have discovered a new ... of the Negro River in the Amazonia State of ... with Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, ... of the journal Proceedings of the Natural Sciences ...
(Date:4/22/2014)... of nanotechnology researchers at the University of Kentucky has ... arrays using RNA. , The research, led by ... in Nanobiotechnology at the UK College of Pharmacy and ... "RNA as a Boiling-Resistant Anionic Polymer Material To Build ... Emil F. Khisamutdinov and Daniel L. Jasinski. , The ...
Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... from the Department of Defense will allow North Carolina ... Institute of Research to further test the effectiveness of ... infections. The two-and-a-half-year project will show the efficacy ... and Dr. John Cavanagh against different types of animal ...
... McMaster University is establishing the first NVIDIA CUDA ... of only twelve worldwide, will teach electrical and ... processing resources available in graphics processing units (GPU) ... CUDA is a parallel computing architecture that enables ...
... antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, and ... new treatment for a parasitic disease that affects almost ... the guiding light for future development of drugs for ... Chemistry . In the study, Rima McLeod and ...
Cached Biology News:NC State research grant will help military combat infections 2McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2
...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
...
... SureLINK HRP Conjugation Kits are based ... conjugates that are consistent and reproducible. ... to conjugate your protein or antibody, ... storage buffer. Activated HRP is ...
Biology Products: